Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus apatinib for third-line advanced colorectal cancer
ChiCTR2000029659Phase 4Recruiting
- Sponsor
- The Affiliated Hospital of Jiangnan University
- Start
- Feb 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab and Rivoceranib in colorectal cancer (CRC), sponsored by The Affiliated Hospital of Jiangnan University. Primary endpoint: Progression-free survival. Started Feb 2020; status: recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2000029659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029659.